Identification of Biomarkers in Dupuytren's Disease by Comparative Analysis of Fibroblasts Versus Tissue Biopsies in Disease-Specific Phenotypes

Journal of Hand Surgery

Volumn 34, Issue 1, 2009, Pages 124-136

  Shih, Barbara ^a   Wijeratne, Dulharie ^a   Armstrong, Daniel J ^a   Lindau, Tommy ^a   Day, Philip ^a   Bayat, Ardeshir ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Biomarkers; Dupuytren's contracture; Dupuytren's disease; Dupuytren's tissue and fibroblasts culture; RT qPCR

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 12; ADAM PROTEIN; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1 FAMILY MEMBRER A1; BIOLOGICAL MARKER; HOMEODOMAIN PROTEIN; IROQUOIS HOMEOBOX PROTEIN 6; PROTEOGLYCAN; PROTEOGLYCAN 4; TENASCIN; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOINFORMATICS; BIOPSY; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; DUPUYTREN CONTRACTURE; FIBROBLAST; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC LINKAGE; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

ADAM PROTEINS; AGED; ALDEHYDE DEHYDROGENASE; BIOPSY; CELL ADHESION MOLECULES; CELLS, CULTURED; DUPUYTREN'S CONTRACTURE; FASCIA; FIBROBLASTS; GENE EXPRESSION; GENETIC MARKERS; HOMEODOMAIN PROTEINS; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; PHENOTYPE; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TENASCIN; TRANSCRIPTION FACTORS;

EID: 58149094315     PISSN: 03635023     EISSN: 15316564     Source Type: Journal    
DOI: 10.1016/j.jhsa.2008.09.017     Document Type: Article

References (72)

1. Bayat A., Cunliffe E.J., and McGrouther D.A. Assessment of clinical severity in Dupuytren's disease. Br J Hosp Med 68 (2007) 604-609
2. Bayat A., Watson J.S., Stanley J.K., Ferguson M.W.J., and Ollier W.E.R. Genetic susceptibility to Dupuytren disease: association of Zf9 transcription factor gene. Plast Reconstr Surg 111 (2003) 2133-2139
3. Hindocha S., John S., Stanley J.K., Watson S.J., and Bayat A. The heritability of Dupuytren's disease: familial aggregation and its clinical significance. J Hand Surg 31 (2006) 204-210
4. Dias J.J., and Braybrooke J. Dupuytren's contracture: an audit of the outcomes of surgery. J Hand Surg 31B (2006) 514-521
5. Hurst L.C., and Badalamente M.A. Nonoperative treatment of Dupuytren's disease. Hand Clin 15 (1999) 97-107
6. Rodrigo J.J., Niebauer J.J., Brown R.L., and Doyle J.R. Treatment of Dupuytren's contracture-long-term results after fasciotomy and fascial excision. J Bone Joint Surg 58A (1976) 380-387
7. Bayat A., and McGrouther D.A. Management of Dupuytren's disease-clear advice for an elusive condition. Ann R Coll Surg Engl 88 (2006) 3-8
8. Buttner J. Reference materials and reference methods in laboratory medicine: a challenge to international cooperation. Eur J Clin Chem Clin Biochem 32 (1994) 571-577
9. Hart M.G., and Hooper G. Clinical associations of Dupuytren's disease. Postgrad Med J 81 (2005) 425-428
10. Rehman S., Salway F., Stanley J.K., Ollier W.E.R., Day P., and Bayat A. Molecular phenotypic descriptors of Dupuytren's disease defined using informatics analysis of the transcriptome. J Hand Surg 33 (2008) 359-372
11. Moyer K.E., Banducci D.R., Graham W.P., and Ehrlich H.P. Dupuytren's disease: physiologic changes in nodule and cord fibroblasts through aging in vitro. Plast Reconstr Surg 110 (2002) 187-193
12. Gabbiani G., and Majno G. Dupuytrens contracture - fibroblast contraction - ultrastructural study. Am J Pathol 66 (1972) 131-146
13. Saar J.D., and Grothaus P.C. Dupuytren's disease: an overview. Plast Reconstr Surg 106 (2000) 125-134
14. O'Gorman D.B., Wu Y., Seney S., Zhu R.D., and Bing S.G. Wnt expression is not correlated with beta-catenin dysregulation in Dupuytren's disease. J Negative Results Biomed (2006) 5-13
15. Dangles V., Lazar V., Validire P., Richon S., Wertheimer M., Laville V., et al. Gene expression profiles of bladder cancers: evidence for a striking effect of in vitro cell models on gene patterns. Br J Cancer 86 (2002) 1283-1289
16. Ord J.J., Streeter E.H., Roberts I.S.D., Cranston D., and Harris A.L. Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer. Br J Cancer 93 (2005) 346-354
17. Galligan C.L., Baig E., Bykerk V., Keystone E.C., and Fish E.N. Distinctive gene expression signatures in rheumatoid arthritis synovial tissue fibroblast cells: correlates with disease activity. Genes Immunity 8 (2007) 480-491
18. Santin A.D., Zhan F., Bellone S., Palmieri M., Cane S., Bignotti E., et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 112 (2004) 14-25
19. Hu F.Z., Nystrom A., Ahmed A., Dopico R., Mossberg I., Palmquist M., et al. Mapping a gene for dupuytren contracture in two Swedish families. Am J Hum Genet 71 (2002) 439-439.
20. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3 (2002) research0034.0031-research0034.0011.
21. Zhang X.Z., Ding L., and Sandford A.J. Selection of reference genes for gene expression studies in human neutrophils by real-time PCR. BMC Mol Biol 6 (2005) 4
22. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25 (2001) 402-408
23. Yuan J.S., and Stewart Jr. C.N. Real-time PCR statistics. PCR Encyclopedia 1 (2005) 101127-101149
24. Atfi A., Dumont E., Colland F., Bonnier D., L'Helgoualc'h A., Prunier C., et al. The disintegrin and metalloproteinase ADAM12 contributes to TGF-beta signaling through interaction with the type II receptor. J Cell Biol 178 (2007) 201-208
25. Le Pabic H., L'Helgoualc'h A., Coutant A., Wewer U.M., Baffet G., Clement B., et al. Involvement of the serine/threonine p70(S6) kinase in TGF-beta 1-induced ADAM12 expression in cultured human hepatic stellate cells. J Hepatol 43 (2005) 1038-1044
26. Seifert O., Bayat A., Geffers R., Dienus K., Buer J., Lofgren S., et al. Identification of unique gene expression patterns within different lesional sites of keloids. Wound Repair Regen 16 (2008) 254-265
27. Le Pabic H., Bonnier D., Wewer U.M., Coutand A., Musso O., Baffet G., et al. ADAM12 in human liver cancers: TGF-β-regulated expression in stellate cells is associated with matrix remodeling. Hepatology 37 (2003) 1056-1066
28. Frohlich C., Albrechtsen R., Dyrskjot L., Rudkjaer L., Orntoft T.F., and Wewer U.M. Molecular profiling of ADAM12 in human bladder cancer. Clin Cancer Res 12 (2006) 7359-7368
29. Kveiborg M., Frohlich C., Albrechtsen R., Tischler V., Dietrich N., Holck P., et al. A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res 65 (2005) 4754-4761
30. Rocks N., Paulissen G., El Hour M., Quesada F., Crahay C., Gueders M., et al. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie 90 (2008) 369-379
31. Purohit V., and Brenner D.A. Mechanisms of alcohol-induced hepatic fibrosis: a summary of the Ron Thurman Symposium. Hepatology 43 (2006) 872-878
32. Kozma E.M., Olczyk K., Wisowski G., Glowacki A., and Bobinski R. Alterations in the extracellular matrix proteoglycan profile in Dupuytren's contracture affect the palmar fascia. J Biochem 137 (2005) 463-476
33. Satish L., LaFramboise W., O'Gorman D., Johnson S., Janto B., Gan B., et al. Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren's contracture. BMC Med Genomics (2008) 1-10
34. Erkan M., Kleeff J., Gorbachevski A., Reiser C., Mitkus T., Esposito I., et al. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 132 (2007) 1447-1464
35. Försti A., Jin Q., Altieri A., Johansson R., Wagner K., Enquist K., et al. Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis. Breast Cancer Res Treatment 101 (2007) 83-93
36. Kim C.J., Isono T., Tambe Y., Chan T., Okabe H., Okada Y., et al. Role of alternative splicing of periostin in human bladder carcinogenesis. Int J Oncol 32 (2008) 161-169
37. Li J.S., Sun G.W., Wei X.Y., and Tang W.H. Expression of periostin and its clinicopathological relevance in gastric cancer. World J Gastroenterol 13 (2007) 5261-5266
38. Shimazaki M., and Kudo A. Impaired capsule formation of tumors in periostin-null mice. Biochem Biophys Res Commun 367 (2008) 736-742
39. Siriwardena B.S.M.S., Kudo Y., Ogawa I., Kitagawa M., Kitajima S., Hatano H., et al. Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer. Br J Cancer 95 (2006) 1396-1403
40. Tilman G., Mattiussi M., Brasseur F., van Baren N., and Decottignies A. Human periostin gene expression in normal tissues, tumors and melanoma: evidences for periostin production by both stromal and melanoma cells. Mol Cancer 80 (2007) 6
41. Kudo Y., Siriwardena B., Hatano H., Ogawa I., and Takata T. Periostin: novel diagnostic and therapeutic target for cancer. Histol Histopathol 22 (2007) 1167-1174
42. Qian A., Meals R.A., Rajfer J., and Gonzalez-Cadavid N.F. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 64 (2004) 399-404
43. Berndt A., Kosmehl H., Katenkamp D., and Tauchmann V. Appearance of the myofibroblastic phenotype in Dupuytren's disease is associated with a fibronectin, laminin, collagen type-IV and tenascin extracellular-matrix. Pathobiology 62 (1994) 55-58
44. Thompson H.G.R., Mih J.D., Krasieva T.B., Tromberg B.J., and George S.C. Epithelial-derived TGF-beta 2 modulates basal and wound-healing subepithelial matrix homeostasis. Am J Physiol Lung Cell Mol Physiol 291 (2006) L1277-L1285
45. Wehrhan F., Rodel F., Grabenbauer G.G., Amann K., Bruckl W., and Schultze-Mosgau S. Transforming growth factor beta 1 dependent regulation of tenascin-C in radiation impaired wound healing. Radiothera Oncol 72 (2004) 297-303
46. Erickson H.P. Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. Curr Opin Cell Biol 5 (1993) 869-876
47. Geffrotin C., Tricaud Y., Crechet F., Castelli M., Lefaix J.L., and Vaiman M. Unlike tenascin-X, tenascin-C is highly up-regulated in pig cutaneous and underlying muscle tissue developing fibrosis after necrosis induced by very high-dose gamma radiation. Radiat Res 149 (1998) 472-481
48. Tamaoki M., Imanaka-Yoshida K., Yokoyama K., Nishioka T., Inada H., Hiroe M., et al. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 167 (2005) 71-80
49. Trebaul A., Chan E.K., and Midwood K.S. Regulation of fibroblast migration by tenascin-C. Biochem Soc Trans 35 (2007) 695-697
50. Bayat A., Stanley J.K., Watson J.S., Ferguson M.W.J., and Ollier W.E.R. Genetic susceptibility to Dupuytren's disease: transforming growth factor beta receptor (TGFβR) gene polymorphisms and Dupuytren's disease. Br J Plast Surg 56 (2003) 328-333
51. Lucas G., Brichet A., Roquelaure Y., Leclerc A., and Descatha A. Dupuytren's disease: personal factors and occupational exposure. Am J Industrial Med 51 (2008) 9-15
52. Johnston P., Chojnowski A.J., Davidson R.K., Riley G.P., Donell S.T., and Clark I.M. A complete expression profile of matrix-degrading metalloproteinases in Dupuytren's disease. J Hand Surg 32A (2007) 343-351
53. Badalamente M.A., Sampson S.P., Hurst L.C., Dowd A., and Miyasaka K. The role of transforming growth factor beta in Dupuytren's disease. J Hand Surg 21 (1996) 210-215
54. Houweling A.C., Dildrop R., Peters T., Mummenhoff J., Moorman A.F.M., Rüther U., et al. Gene and cluster-specific expression of the Iroquois family members during mouse development. Mech Dev 107 (2001) 169-174
55. Van Tuyl M., Liu J., Groenman F., Ridsdale R., Han R.N.N., Venkatesh V., and Post M. Iroquois genes influence proximo-distal morphogenesis during rat lung development. Am J Physiol Lung Cell Mol Physiol 290 (2006) L777-L789
56. Bignotti E., Tassi R.A., Calza S., Ravaggi A., Romani C., Rossi E., et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol 103 (2006) 405-416
57. Beer T., Myrthue A., Beer T., Myrthue A., Beer T., and Myrthue A. IRX5 inhibition as treatment for hyperproliferative disorders. World Intellectual Property Organization wo/2005/110464 (2005)
58. Lesche R., Peetz A., vanderHoeven F., and Ruther U. Ft1, a novel gene related to ubiquitin-conjugating enzymes, is deleted in the fused toes mouse mutation. Mamm Genome 8 (1997) 879-883
59. Corsino P., Davis B., Law M., Chytil A., Forrester E., Norgaard P., et al. Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression. Cancer Res 67 (2007) 3135-3144
60. Meister P., Gokel J.M., and Remberger K. Palmar fibromatosis-Dupuytren's contracture: a comparison of light electron and immunofluoresence microscopic findings. Pathol Res Pract 164 (1979) 402-412
61. Weiskirchen R., Moser M., Weiskirchen S., Erdel M., Dahmen S., Buettner R., et al. LIM-domain protein cysteine- and glycine-rich protein 2 (CRP2) is a novel marker of hepatic stellate cells and binding partner of the protein inhibitor of activated STAT1. Biochem J 359 (2001) 485-496
62. Lee L.C., Zhang A.Y., Chong A.K., Pham H., Longaker M.T., and Chang J. Expression of a novel gene, MafB, in Dupuytren's disease. J Hand Surg 31A (2006) 211-218
63. Vadasz Z., Kessler O., Akiri G., Gengrinovitch S., Kagan H.M., Baruch Y., et al. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J Hepatol 43 (2005) 499-507
64. Krull N.B., and Gressner A.M. Differential expression of keratan sulphate proteoglycans fibromodulin, lumican and aggrecan in normal and fibrotic rat liver. FEBS Lett 312 (1992) 47-52
65. Oda R., Suardita K., Fujimoto K., Pan H., Yan W., Shimazu A., et al. Anti-membrane-bound transferrin-like protein antibodies induce cell-shape change and chondrocyte differentiation in the presence or absence of concanavalin A. J Cell Sci 116 (2003) 2029-2038
66. Rogers D.F., and Barnes P.J. Treatment of airway mucus hypersecretion. Ann Med 38 (2006) 116-125
67. Naugle J.E., Olson E.R., Zhang X.J., Mase S.E., Pilati C.F., Maron M.B., et al. Type VI collagen induces cardiac myofibroblast differentiation: implications for postinfarction remodeling. Am J Physiol Heart Circ Physiol 290 (2006) H323-H330
68. Banfi P., Lanzi C., Falvella F.S., Gariboldi M., Gambetta R.A., and Dragani T.A. The daunorubicin-binding protein of M(r) 54,000 is an aldehyde dehydrogenase and is down-regulated in mouse liver tumors and in tumor cell lines. Mol Pharmacol 46 (1994) 896-900
69. Dragani T.A., Falvella F.S., Manenti G., Pierotti M.A., and Gambetta R.A. Downexpression of aldehyde dehydrogenase 1 in murine lung tumors. Mol Carcinog 16 (1996) 123-125
70. Bensadoun E.S., Burke A.K., Hogg J.C., and Roberts C.R. Proteoglycan deposition in pulmonary fibrosis. Am J Respir Crit Care Med 154 (1996) 1819-1828
71. Klahr S., and Morrissey J.J. Comparative study of ACE inhibitors and angiotensin II receptor antagonists in interstitial scarring. Kidney Int 63 (1997) S111-S114
72. Ogata I., Auster A.S., Matsui A., Greenwel P., Geerts A., Damico T., et al. Up-regulation of type I procollagen C-proteinase enhancer protein messenger RNA in rats with CCl4-induced liver fibrosis. Hepatology 26 (1997) 611-617